type 17 immunity and arthritis

Tue23  Feb12:05pm(20 mins)
Conference Room 2
Dr Hussein Al-Mossawi


Th17 immunity emerged as a distinct lineage of T cell effector function in 2005. Since then, the type 17 immune response has been the focus of much research culminating in a number of therapeutic approaches that target this pathway. The role of this pathway in human disease was initially highlighted by genetic polymorphisms implicating it in a number of immune-mediated inflammatory diseases. In addition to the many successes in clinical trials, there have also been failures that have provided the opportunity to understand the role of this pathway in a number of human diseases. Targeting IL-17A and F in inflammatory arthritis has shown efficacy in the MHC-I associated diseases such as ankylosing spondylitis and psoriatic arthritis but not in MHC-II associated rheumatoid arthritis. Additionally, targeting the effector cytokines IL-17A and F has proven more successful for arthritis than the upstream cytokine IL-23 suggesting a role for IL-23-indpendent type 17 immunity in inflammatory joint disease.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021